Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

Texas MPN Workshop 2020 | Targeted therapies in combination with ruxolitinib

Lucia Masarova • 21 Aug 2020
Texas MPN Workshop 2020
Myelofibrosis Azacitidine Buparlisib Navitoclax Pelabresib Ruxolitinib
MANIFEST

Lucia Masarova, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, updates us on the use of novel targeted therapies in combination with ruxolitinib, a JAK inhibitor. These include results of the MANIFEST study (NCT02158858) combining a BET inhibtor with ruxolitinib in myelofibrosis, azaciditine with ruxolitinib, as well as studies evaluating the BCL-2 inhibitor, venetoclax in combination with JAK inhibition. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Lucia Masarova

Insights into the current role of ropeginterferon in the ET treatment landscape
3:31
Insights into the current role of ropeginterferon in the ET treatment landscape
Lucia Masarova • 4 Oct 2026
Emerging therapeutic strategies and future directions in MPNs
3:00
Emerging therapeutic strategies and future directions in MPNs
Lucia Masarova • 4 Oct 2026
Novel agents and approaches being explored in second-line myelofibrosis
14:29
Novel agents and approaches being explored in second-line myelofibrosis
Claire Harrison et al. • 2 Oct 2026
SURPASS-ET: switching to ropeginterferon alfa-2b improves hematologic control in ET
1:35
SURPASS-ET: switching to ropeginterferon alfa-2b improves hematologic control in ET
Lucia Masarova • 13 Jun 2026

Related Videos

When to switch JAK inhibitor therapy in myelofibrosis
1:08
When to switch JAK inhibitor therapy in myelofibrosis
John Mascarenhas • 1 Oct 2026
Long-term spleen response with combination therapy in myelofibrosis: MANIFEST-2
1:36
Long-term spleen response with combination therapy in myelofibrosis: MANIFEST-2
John Mascarenhas • 1 Oct 2026
Emerging therapeutic strategies and future directions in MPNs
3:00
Emerging therapeutic strategies and future directions in MPNs
Lucia Masarova • 4 Oct 2026
MPN Progression Registry: insights into the work of the MPN Research Foundation
19:15
MPN Progression Registry: insights into the work of the MPN Research Foundation
David Shoultz et al. • 2 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals